AVID200

AVID200 is a rationally designed, first-in-class recombinant fusion protein that acts as a selective inhibitor of transforming growth factor beta (TGF-beta) isoforms 1 and 3. It functions as an anti-TGF-beta trap by fusing the ectodomains of TGF-beta receptors to a human Fc domain, thereby sequestering and neutralizing TGF-beta1 and TGF-beta3 with high potency while sparing TGF-beta2[1][5][7]. This selectivity aims to avoid cardiac and other toxicities associated with non-selective inhibition. Mechanistically, AVID200 blocks the immunosuppressive effects of these isoforms in the tumor microenvironment, reverses fibrosis-related signaling, and can render tumors more sensitive to immune checkpoint blockade therapies[5][6]. It has demonstrated pharmacodynamic activity by reducing SMAD2 phosphorylation in patient samples[6], suppressing plasma TGFβ1 levels in myelofibrosis cells[2], and modulating immune activation markers in clinical studies[6]. AVID200 is under investigation for several indications including advanced myelofibrosis (MF), solid tumors, and systemic sclerosis; it has received orphan drug designation for systemic sclerosis[4].

Other names

Tgf-.beta. ligand trap comprised of tgf-.beta. receptor ectodomains fused to a human fc domain avid-200Tgf-beta 1/3 inhibitor avid200Tgfbeta receptor ectodomain-igg fc fusion protein avid200